2026-10-14T00:30:14Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33963202 2026-09-22T08:27:13Z category_7 portal_147 item_type_3 month_year_09_2026

Supplemental Material for:Comprehensive quality of life assessment in advanced renal cell carcinoma: Final results of the PRO Kidney study figshare admin karger (2628495) Tilman Kirste (25088604) Michael Scheffler (25088607) Ralf Eckert (25088608) Henning Pelz (19203145) Lothar Müller (18830970) Oswald Burkhard (25088609) Jacqueline Rauh (25088611) Thorsten Werner (8615628) Harald-Robert Bruch (3144795) Klaus-Ulrich Däßler (25088612) Harald Junius (25088615) Arnd Nusch (18480521) Nicole Hamm (569562) Marco Chiabudini (9769430) Karin Potthoff (7238717) Medicine medicine <p dir="ltr"><b>Introduction: </b>Patient-reported outcomes (PROs), particularly health-related quality of life (HRQoL) and treatment-related side effects, are crucial for guiding treatment in advanced renal cell carcinoma (aRCC). <a href="" target="_blank">We report longitudinal PRO data prospectively collected in a real-world aRCC setting during the targeted therapy era.</a></p><p dir="ltr"><b>Methods: </b>Patients with aRCC were enrolled in the prospective, observational, multicenter PRO Kidney cohort study (NCT02537743) from 2015-2018. PROs were assessed tablet-based from baseline up to 24 months using validated instruments (NCCN‑FACT FKSI‑19, FACIT‑Fatigue), and custom questions on RCC-/treatment-specific symptoms (IOAE) and daily life impact (IODAYA). Descriptive statistics were used, except for time-to-deterioration (TTD) analysis.</p><p dir="ltr"><b>Results:</b> Of 98 patients signing informed consent, 90 with at least one completed PRO questionnaire were included in the full analysis set; 80 with baseline questionnaires were analyzed for HRQoL. Median age was 68 years; 78.9% (n=71) presented with clear-cell histology and 44.4% (n=40) were at intermediate MSKCC risk. The most frequently used first-line treatments were pazopanib (56.7%; n=51) and sunitinib (23.3%; n=21). Clinically relevant deterioration in HRQoL was observed in 52.5% (n=42) of patients within six months (median TTD 5.1 months, 95%CI 2.9-7.0). Treatment was associated with fatigue, nausea, diarrhea and altered taste, independent of treatment regimen. Most patients reported being content with their HRQoL and were able to continue with their day-to-day activities.</p><p dir="ltr"><b>Conclusion:</b> Despite treatment-related side effects and HRQoL deterioration in some patients, most maintained daily functioning and reported acceptable overall HRQoL, suggesting that tyrosine kinase inhibitor monotherapy may remain a valuable option, particularly for those with contraindications to immunotherapy.</p> 2026-09-22T08:27:13Z Dataset Dataset 10.6084/m9.figshare.33963202.v1 https://figshare.com/articles/dataset/Supplemental_Material_for_Comprehensive_quality_of_life_assessment_in_advanced_renal_cell_carcinoma_Final_results_of_the_PRO_Kidney_study/33963202 CC BY 4.0